Clinical trials: Healthy Volunteer Subjects
Chronic Obstructive Pulmonary Disease
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
The purpose of this study is to evaluate the effect of single doses of therapeutic and supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy subjects compared with placebo.
- Trial name
- CT14 (NCT00777595)
- Testing
- CHF 4226 pMDI, Moxifloxacin
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Male Volunteers
A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects
The study (E3112/CP1) is a single-center, randomized, double-blind, placebo-controlled, single intravenous ascending dose study conducted in Japanese healthy adult males to evaluate the pharmacokinetics (PK), safety, and…
- Trial name
- NCT03014895
- Testing
- E3112
- Where
- Japan
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- EA Pharma Co., Ltd.
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects.
- Trial name
- NCT04525079
- Testing
- CT-P59
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Celltrion
Healthy
Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions
The objective of this study is to compare the rate and extent of absorption of amoxicillin-clavulanic acid 400 mg-57 mg chewable tablets (test) versus Augmentin® (reference) administered as 1 x 400 mg-57 mg chewable tablet under…
- Trial name
- NCT00836901
- Testing
- amoxicillin-clavulanic acid, Augmentin®
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
PET Study of Repeated ASN51 in Healthy Volunteers
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs)…
- Trial name
- NCT05725005
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Healthy Volunteers
A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants
The purpose of this study is to characterize the effect of itraconazole (Part 1) and rifampin (Part 2) on the single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult…
- Trial name
- NCT03928327
- Testing
- TAK-788, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy Volunteers
Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of isotopologs of Atazanavir both as single agents and as combinations.
- Trial name
- NCT01458769
- Testing
- C-10276, C-10297, C-10299
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Concert Pharmaceuticals
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Asthma
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.
- Trial name
- NCT01310322
- Testing
- AZD5423
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease, Healthy Volunteer
Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
The primary objective of the study is to evaluate the safety and tolerability of single-ascending intravenous (IV) infusions of BIIB076 in healthy volunteers and participants with Alzheimer's disease (AD).
- Trial name
- NCT03056729
- Testing
- BIIB076
- Where
- 8 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food
The purpose of the study is to evaluate the amount of GLPG1837 and metabolite present in the blood (relative bioavailability) after a single oral administration of 500 mg GLPG1837 given as an oral suspension under fasted…
- Trial name
- NCT02562859
- Testing
- 500 mg GLPG1837 as oral suspension, 500 mg GLPG1837 as oral tablet
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration (ascending dose levels) under fasted condition, to characterize the pharmacokinetics…
- Trial name
- NCT03180762
- Testing
- JNJ-64140284 0.1 mg, JNJ-64140284 0.5 mg, JNJ-64140284 2.5 mg
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Hepatic Insufficiency
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
This study is designed to evaluate the safety and pharmacokinetic effects of indacaterol in subjects with impaired liver function in comparison with healthy subjects
- Trial name
- NCT00416702
- Testing
- QAB149
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Novartis
Healthy
Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000 mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
- Trial name
- NCT01913002
- Testing
- LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Ulcerative Colitis
TP0501 - Pharmaco-Scintigraphic-Study
This is a Phase I, open-label, single-site trial to evaluate the drug release, using Scintigraphic images and mesalazine plasma levels (PK) in healthy subjects.
- Trial name
- NCT02306772
- Testing
- TP05 Coating A, TP05 Coating B
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tillotts Pharma AG
Alzheimer's Disease
Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation
The purpose of this study is to find a modified release oral tablet formulation for this drug, which will be safe and well tolerated.
- Trial name
- NCT02710188
- Testing
- HTL0009936 modified release, HTL0009936 immediate release
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Acute Coronary Syndromes
Drug Interaction Statin
This purpose of this study is to assess the effects of BMS-919373 on the single dose Pharmacokinetics (PK) of Rosuvastatin and Atorvastatin in healthy subjects.
- Trial name
- NCT02089061
- Testing
- BMS-919373, Rosuvastatin, Atorvastatin
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions
The purpose of this study is to compare the drug levels of darunavir obtained after administration of a single administration of the 800 mg tablet (new formulation) to that following administration of two 400 mg commercial…
- Trial name
- NCT01052883
- Testing
- DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy Volunteers
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3…
- Trial name
- NCT03706469
- Testing
- TAK-831 T2, TAK-831 T3
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Healthy Participants
Study of WPV01 in Healthy Subjects
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WPV01 and WPV01 Co-administrated With Ritonavir in Healthy Adult Subjects.
- Trial name
- NCT06205329
- Testing
- WPV01 Dose 1-4, WPV01 Dose 5-8 and Ritonavir, WPV01 Dose 9-12
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.